Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 5000 iu/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - heparin is indicated for the prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism and occlusive vascular disease. it is also used to prevent thromboembolic complications arising from cardiac and vascular surgery, frostbite, dialysis and other perfusion procedures. heparin is also used as an anticoagulant in blood transfusions

Malta - inglise - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - solution for infusion - tirofiban 50 µg - antithrombotic agents

Lõuna-Aafrika Vabariik - inglise - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - solution - see ingredients - each 1,0 ml solution contains tirofiban hydrochloride (monohydrate) equivalent to tirofiban 0,25 mg

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dipyridamole; aspirin -

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

clinect nz pty limited - pentoxifylline 400mg;  ;   - modified release tablet - 400 mg - active: pentoxifylline 400mg     excipient: erythrosine hyetellose hypromellose macrogol 8000 magnesium stearate povidone purified talc   purified water   titanium dioxide - the treatment of peripheral occlusive vascular disease and circulatory disorders of arteriosclerotic, diabetic, inflammatory or function origin; trophic disorders (e.g., leg ulcers and gangrene).

Iisrael - inglise - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 1 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Iisrael - inglise - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 2 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolism. coumadin is indicated for the prophylaxis and/or treatment of the tromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Iisrael - inglise - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 2.5 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Iisrael - inglise - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 5 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolis. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.